P. Declerck

发表

Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

K. Preissner, P. Declerck, S. Baudner, 1988, The Journal of biological chemistry.

Identification of a bacterial inhibitor against g-type lysozyme

G. Baggerman, C. Michiels, I. W. Nilsen, 2011, Cellular and Molecular Life Sciences.

Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2

T. Kooistra, P. Declerck, D. Collen, 1988, Thrombosis and Haemostasis.

Thrombin activatable fibrinolysis inhibitor

P. Declerck, P. Declerck, 2011, Hämostaseologie.

Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor

S. Muyldermans, A. Gils, G. Hassanzadeh-Ghassabeh, 2010, Journal of thrombosis and haemostasis : JTH.

Characterization of rat thrombin‐activatable fibrinolysis inhibitor (TAFI) – a comparative study assessing the biological equivalence of rat, murine and human TAFI

A. Gils, A. Macovei, G. Compernolle, 2006, Journal of thrombosis and haemostasis : JTH.

Sample preparation for plasma measurement of plasminogen activator inhibitor-1 antigen in large population studies.

E. Meilahn, R. Tracy, P. Declerck, 1993, Archives of pathology & laboratory medicine.

Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays.

P. Declerck, D. Collen, D. Collen, 1990, Thrombosis research. Supplement.

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study

D. Trégouët, E. Lubos, C. Bickel, 2009, Journal of thrombosis and haemostasis : JTH.

Fibrinolytic Response and Fibrin Fragment D-Dimer Levels in Patients with Deep Vein Thrombosis

P. Mombaerts, P. Declerck, P. Holvoet, 1987, Thrombosis and Haemostasis.

Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin‐activatable fibrinolysis inhibitor activation and activated thrombin‐activatable fibrinolysis inhibitor activity

N. Callewaert, P. Declerck, S. Strelkov, 2016, Journal of thrombosis and haemostasis : JTH.

Crystallization and X‐ray diffraction data of the cleaved form of plasminogen activator inhibitor‐1

K. Aertgeerts, P. Declerck, H. D. De Bondt, 1995, Proteins.

Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma.

P. Declerck, D. Collen, I. Juhan-vague, 1991, Thrombosis research.

Modulation of TAFI function through different pathways – implications for the development of TAFI inhibitors

A. Gils, P. Declerck, A. Macovei, 2005, Journal of thrombosis and haemostasis : JTH.

Comparative evaluation of stable TAFIa variants: importance of α‐helix 9 and β‐sheet 11 for TAFIa (in)stability

A. Gils, M. de Maeyer, P. Declerck, 2007, Journal of thrombosis and haemostasis : JTH.

High quality structure of cleaved PAI-1-stab.

P. Declerck, S. Strelkov, M. Dewilde, 2009, Journal of structural biology.

Lysozyme inhibitor conferring bacterial tolerance to invertebrate type lysozyme

A. Aertsen, C. Michiels, G. Compernolle, 2010, Cellular and Molecular Life Sciences.

Expression and Characterization of Recombinant Porcine Plasminogen Activator Inhibitor-1

P. Declerck, A. Bijnens, E. Kruithof, 1997, Thrombosis and Haemostasis.

Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines.

P. Declerck, S. Brichard, C. Halleux, 1999, The Journal of clinical endocrinology and metabolism.

Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.

D. Vaughan, P. Declerck, D. Collen, 1989, The Journal of clinical investigation.

Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).

L. Nelles, P. Declerck, D. Collen, 1988, European journal of biochemistry.

[Plasminogen activator-inhibitor 1: biochemical, structural and functional studies].

P. Declerck, 1993, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

Multicenter Evaluation of Commercially Available Methods for the Immunological Determination of Plasminogen Activator Inhibitor-1 (PAI-1)

P. Declerck, J. Jespersen, C. Kluft, 1993, Thrombosis and Haemostasis.

Prevalence and Induction of Circulating Antibodies against Recombinant Staphylokinase

P. Declerck, H. Moreau, D. Collen, 1994, Thrombosis and Haemostasis.